Xiaoyun Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyun Huang has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Guanghui Liu
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications - Guoxin Li
Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
10 shared publications - Hao Liu
Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications - Jingsi Liu
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications - Kaibiao Xu
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications - Qianhui Zheng
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications
Latest Publications
- Open Access
Pan-Cancer Driver Mutation Signatures Define a Molecular Taxonomy of Tumors
Cancers with similar histology often exhibit divergent clinical behavior, reflecting molecular heterogeneity not captured by current classification systems. Although driver mutations are central to tumorigenesis, their broader systems-level consequences have not been systematically leveraged. We integrated genomic and transcriptomic data across cancers to define driver mutation signatures (DMS), coordinated transcriptional programs associated with cancer driver mutations. From 121 candidate drivers, we derived 90 robust signatures and quantified their activity in individual tumors using mutation signature scores (MSS). DMS analysis revealed a hierarchical organization of tumors into molecular subgroups that transcended tissue boundaries while preserving driver-associated features. Continuous MSS profiles further defined high-resolution molecular fingerprints for individual tumors. DMS provides a quantitative framework for tumor classification and patient stratification and links driver-associated programs to potential therapeutic vulnerabilities. Together, these findings establish a pan-cancer molecular taxonomy that bridges genotype and phenotype and may inform precision oncology.
Open AccessPan-Cancer Driver Mutation Signatures Define a Molecular Taxonomy of Tumors
Cancers with similar histology often exhibit divergent clinical behavior, reflecting molecular heterogeneity not captured by current classification systems. Although driver mutations are central to tumorigenesis, their broader systems-level consequences have not been systematically leveraged. We integrated genomic and transcriptomic data across cancers to define driver mutation signatures (DMS), coordinated transcriptional programs associated with cancer driver mutations. From 121 candidate drivers, we derived 90 robust signatures and quantified their activity in individual tumors using mutation signature scores (MSS). DMS analysis revealed a hierarchical organization of tumors into molecular subgroups that transcended tissue boundaries while preserving driver-associated features. Continuous MSS profiles further defined high-resolution molecular fingerprints for individual tumors. DMS provides a quantitative framework for tumor classification and patient stratification and links driver-associated programs to potential therapeutic vulnerabilities. Together, these findings establish a pan-cancer molecular taxonomy that bridges genotype and phenotype and may inform precision oncology.
- Open Access
- 3 February 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (5) , 1270-1300
Toll signaling controls stem cell proliferation in intestinal regeneration and tumorigenesis
The Drosophila Toll/NF-κB pathway has been extensively studied for its roles in innate immunity and embryonic development. Nevertheless, the regulatory mechanisms underlying Spz/Toll signaling in non-immune contexts remain poorly understood. Here, we demonstrate a critical role for Toll in regulating intestinal stem cell activity through direct transcriptional control of PI3K and Akt in an insulin-independent manner. Time-series transcriptomic analysis of intestinal damage and repair responses reveals that the stress-responsive factor Jumu regulates Spz expression to activate Toll signaling. Disruption of the Jumu/Spz/Toll cascade or PI3K/Akt signaling impairs intestinal regeneration and suppresses tumor growth, and epistasis analysis confirms that PI3K/Akt functions downstream of Toll . Our findings elucidate an autocrine Spz/Toll-mediated mechanism that drives stem cell function via the PI3K/Akt pathway during tissue homeostasis and uncover a critical non-immune role of Toll signaling in both physiological and pathological contexts.
- 3 February 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (5) , 1270-1300
Open AccessToll signaling controls stem cell proliferation in intestinal regeneration and tumorigenesis
The Drosophila Toll/NF-κB pathway has been extensively studied for its roles in innate immunity and embryonic development. Nevertheless, the regulatory mechanisms underlying Spz/Toll signaling in non-immune contexts remain poorly understood. Here, we demonstrate a critical role for Toll in regulating intestinal stem cell activity through direct transcriptional control of PI3K and Akt in an insulin-independent manner. Time-series transcriptomic analysis of intestinal damage and repair responses reveals that the stress-responsive factor Jumu regulates Spz expression to activate Toll signaling. Disruption of the Jumu/Spz/Toll cascade or PI3K/Akt signaling impairs intestinal regeneration and suppresses tumor growth, and epistasis analysis confirms that PI3K/Akt functions downstream of Toll . Our findings elucidate an autocrine Spz/Toll-mediated mechanism that drives stem cell function via the PI3K/Akt pathway during tissue homeostasis and uncover a critical non-immune role of Toll signaling in both physiological and pathological contexts.
- Open Access
- 4 December 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2766
Cell-to-Cell and Patient-to-Patient Variability in Antimicrobial Resistance
Antimicrobial resistance (AMR) remains a global health crisis, yet treatment outcomes cannot be explained by resistance genes alone. Increasing evidence highlights the importance of variability at two levels: within bacterial populations and across patients. At the microbial level, cell-to-cell variability including genetic mutations, stochastic gene expression, persister cell formation, heteroresistance, and spatial heterogeneity within biofilms creates phenotypic diversity that allows subsets of bacteria to survive antimicrobial stress. At the host level, patient-to-patient variability including differences in genetic background, immune competence, comorbidities, gut microbiome composition, and pharmacokinetics shapes both susceptibility to resistant infections and the likelihood of treatment success. Together, these dimensions explain why infections with the same pathogen can lead to divergent clinical outcomes. Understanding and integrating both microbial and host variability offers a path toward more precise diagnostics, personalized therapy, and novel strategies to counter AMR.
- 4 December 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2766
Open AccessCell-to-Cell and Patient-to-Patient Variability in Antimicrobial Resistance
Antimicrobial resistance (AMR) remains a global health crisis, yet treatment outcomes cannot be explained by resistance genes alone. Increasing evidence highlights the importance of variability at two levels: within bacterial populations and across patients. At the microbial level, cell-to-cell variability including genetic mutations, stochastic gene expression, persister cell formation, heteroresistance, and spatial heterogeneity within biofilms creates phenotypic diversity that allows subsets of bacteria to survive antimicrobial stress. At the host level, patient-to-patient variability including differences in genetic background, immune competence, comorbidities, gut microbiome composition, and pharmacokinetics shapes both susceptibility to resistant infections and the likelihood of treatment success. Together, these dimensions explain why infections with the same pathogen can lead to divergent clinical outcomes. Understanding and integrating both microbial and host variability offers a path toward more precise diagnostics, personalized therapy, and novel strategies to counter AMR.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Gene Ontology enrichment analysis of differentially expressed genes in TBA-positive vs. TBA-negative gastric cancer cells.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Gene Ontology enrichment analysis of differentially expressed genes in TBA-positive vs. TBA-negative gastric cancer cells.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Kaplan–Meier survival curves for OS in TBA-positive and TBA-negative patients with gastric cancer.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Kaplan–Meier survival curves for OS in TBA-positive and TBA-negative patients with gastric cancer.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Neuronal autoantibody staining patterns and identification of known PNS-related antibodies in patients with gastric cancer. Ab, antibody.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Neuronal autoantibody staining patterns and identification of known PNS-related antibodies in patients with gastric cancer. Ab, antibody.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Reduced CD8+ T-cell infiltration and altered CD4+/CD8+ ratio in TBA-positive gastric cancer tissues. ns, not significant.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Reduced CD8+ T-cell infiltration and altered CD4+/CD8+ ratio in TBA-positive gastric cancer tissues. ns, not significant.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Neuronal autoantibodies have been identified in immune-mediated encephalitis, most of which are related to paraneoplastic neurologic syndromes (PNS). We detected neuronal autoantibodies in patients with gastric cancer without PNS and illustrated their correlation with clinical prognosis. All serum samples were tested by the mouse brain tissue-based assay (TBA) using immunofluorescence for screening neuronal autoantibodies. Known PNS-related neuronal autoantibodies were detected by cell-based assay. A single-center cohort has been started in Nanfang Hospital. The T-cell status of the tumor microenvironment was assessed. Single-cell sequencing was performed with limited tumor samples. Patients were grouped into TBA-positive (n = 144) and TBA-negative (n = 179) groups by the TBA status. Further screening of TBA+ specimens using the cell-based assay method revealed known PNS-related autoantibodies in 13.2% (19/144) of cases. Additionally, TBA-positive patients with gastric cancer exhibited lower CD8+ T-cell infiltration in the tumor tissue. The survival analysis show that neuronal autoantibodies in patients (TBA-positive) were associated with shorter overall survival (OS; P = 0.014). In the multivariate survival analysis, TBA positivity was still associated with shortened OS after adjusting the major covariates (HR = 2.28; 95% confidence interval, 1.31–3.97; P = 0.004). Meanwhile, single-cell sequencing indicates that cell junction assembly and synapse organization may play important roles in biological process. In this cohort study, neuronal autoantibodies were highly prevalent among patients with gastric cancer and were associated with shortened OS and features of immunosuppression within the tumor microenvironment, suggesting a candidate for exploring therapeutic relevance, with further mechanistic studies needed for validation.Significance:Neuronal autoantibodies are prevalent in patients with gastric cancer, and patients without neurologic symptoms are linked to shorter survival and immunosuppression. These results provide a new direction for prognostic biomarkers and targeted therapy exploration.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Neuronal autoantibodies have been identified in immune-mediated encephalitis, most of which are related to paraneoplastic neurologic syndromes (PNS). We detected neuronal autoantibodies in patients with gastric cancer without PNS and illustrated their correlation with clinical prognosis. All serum samples were tested by the mouse brain tissue-based assay (TBA) using immunofluorescence for screening neuronal autoantibodies. Known PNS-related neuronal autoantibodies were detected by cell-based assay. A single-center cohort has been started in Nanfang Hospital. The T-cell status of the tumor microenvironment was assessed. Single-cell sequencing was performed with limited tumor samples. Patients were grouped into TBA-positive (n = 144) and TBA-negative (n = 179) groups by the TBA status. Further screening of TBA+ specimens using the cell-based assay method revealed known PNS-related autoantibodies in 13.2% (19/144) of cases. Additionally, TBA-positive patients with gastric cancer exhibited lower CD8+ T-cell infiltration in the tumor tissue. The survival analysis show that neuronal autoantibodies in patients (TBA-positive) were associated with shorter overall survival (OS; P = 0.014). In the multivariate survival analysis, TBA positivity was still associated with shortened OS after adjusting the major covariates (HR = 2.28; 95% confidence interval, 1.31–3.97; P = 0.004). Meanwhile, single-cell sequencing indicates that cell junction assembly and synapse organization may play important roles in biological process. In this cohort study, neuronal autoantibodies were highly prevalent among patients with gastric cancer and were associated with shortened OS and features of immunosuppression within the tumor microenvironment, suggesting a candidate for exploring therapeutic relevance, with further mechanistic studies needed for validation.Significance:Neuronal autoantibodies are prevalent in patients with gastric cancer, and patients without neurologic symptoms are linked to shorter survival and immunosuppression. These results provide a new direction for prognostic biomarkers and targeted therapy exploration.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Cox proportional hazards regression analysis of factors affecting OS in patients with gastric cancer.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Cox proportional hazards regression analysis of factors affecting OS in patients with gastric cancer.